MREO - Mereo BioPharma Group plc Stock Price & Dividend Safety Sector: Healthcare | Exchange: NASDAQ Global Market Current Price & Safety Score Price: 0.28 USD StockBonds Safety Grade: D Altman Z-Score (Bankruptcy Risk): -18.57 StockBond Score: -0.89 Company Description Mereo BioPharma Group plc a Londonbased biopharmaceutical firm established in 2015 specializes in developing and commercializing innovative therapies for oncology and rare conditions Operating both in the United Kingdom and internationally the company boasts a diverse product pipeline Its primary oncology asset etigilimab OMP313M32 an antibody Tcell immunoreceptor is presently undergoing Phase 1b clinical investigation for tumor treatment Another cancer compound Navicixizumab OMP305B83 has already concluded its Phase 1b clinical studies for patients battling latestage ovarian cancer Beyond cancer Mereo is advancing several other promising candidates These include Acumapimod BCT197 a p38 MAP kinase inhibitor which is currently in Phase II clinical trials for addressing acute exacerbations of chronic obstructive pulmonary disease Additionally Leflutrozole BGS649 an oral aromatase inhibitor is being developed to manage hypogonadotropic hypogonadism Within its rare disease portfolio Mereo features Setrusumab BPS804 a novel antibody designed to treat osteogenesis imperfecta and Alvelestat MPH966 an oral small molecule in Phase II clinical trials for Alpha1 antitrypsin deficiency To bolster its research Mereo BioPharma collaborates with The University of Texas MD Anderson Cancer Center focusing on the evaluation of its antiTIGIT therapeutic antibody candidate etigilimab